The flourishing Medical Marijuana Market in Europe is expected to rise from $3,414.26 million in 2022 to $9,703.38 million in 2028, a 19.0% CAGR.
Medical Marijuana Market in Europe is Rising (Photo from Global market Insights)
Medical Marijuana Market in Europe Surges: Legalization Sparks Growth in Germany, France, and the UK
Medical Marijuana Market in Europe legalization is driving this trend. Germany, France, and the UK are pioneers in cannabis therapy. Germany has an established medicinal marijuana market, France is running a pilot program, and the UK has strengthened patient access regulations. These projects show how EU medicinal marijuana adoption is changing.
The industry of Medical Marijuana Market in Europe is divided into Germany, the UK, France, Italy, Spain, and the Rest. Germany holds the greatest market share and is predicted to rise due to regional life science research spending.
Extract forms—dried and extract—dominate the market. Extract forms are becoming more popular. Pain management, which treats Tourette’s, Alzheimer’s, cancer, and other illnesses, dominates the market.
READ ALSO: Iowa Health Officials Take Action To Curb Maternal Deaths
Retail Pharmacies Lead as Medical Marijuana Market in Europe Thrives
Retail pharmacies dominate distribution networks. E-commerce and other outlets follow. Germany dominates the Medical Marijuana Market in Europe.
Aphria, Inc., Canopy Growth Corporation, GW Pharmaceuticals, Panaxia Pharmaceutical Industries Ltd., and VIVO Cannabis Inc. drive market growth. Their efforts confirm the market’s potential and highlight medical marijuana’s continued developments and investments.
The thorough study sheds light on market dynamics, segmentation, and significant firms impacting the medical marijuana market as it evolves and gains popularity. Cannabis’ therapeutic effects are becoming more widely recognized, making the Medical Marijuana Market in Europe exciting and dynamic.
READ ALSO: Measles Cases As A Deadly Virus: Spreading Globally
